News
BMRN
81.47
-10.67%
-9.73
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
Biomarin Pharmaceutical (NASDAQ:BMRN) has an average price target of $100.88. 8 analysts have released ratings for the company in the last three months. The company's focus is on rare-disease therapies. Analysts have set 12-month price targets for biomarin pharmaceutical of $110.00.
Benzinga · 4h ago
BioMarin Pharmaceutical Is Maintained at Sector Perform by Scotiabank
Dow Jones · 4h ago
BioMarin Pharmaceutical Price Target Raised to $85.00/Share From $83.00 by Scotiabank
Dow Jones · 4h ago
Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $85
Benzinga · 4h ago
BUZZ-BioMarin falls after Q1 revenue miss
BioMarin Pharmaceutical shares fall 10.8% to $81.35. Company reported Q1 revenue of $648.80 million, missing analysts' average expectation of $651.80 mln. Stock down 15.8 percent year-to-date; down 10.7% from Tuesday's close.
Reuters · 4h ago
BIOMARIN PHARMACEUTICAL INC <BMRN.O>: CANACCORD GENUITY CUTS TARGET PRICE TO $89 FROM $91
Reuters · 4h ago
BioMarin Pharmaceutical Price Target Maintained With a $110.00/Share by Cantor Fitzgerald
Dow Jones · 5h ago
Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
Benzinga · 5h ago
BioMarin Pharmaceutical Is Maintained at Overweight by Wells Fargo
Dow Jones · 5h ago
BioMarin Pharmaceutical Price Target Raised to $110.00/Share From $100.00 by Wells Fargo
Dow Jones · 5h ago
Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $110
Benzinga · 5h ago
BIOMARIN PHARMACEUTICAL SHARES DOWN 8.1% AFTER Q1 REV MISS
Reuters · 6h ago
BIOMARIN PHARMACEUTICAL INC <BMRN.O>: CITIGROUP CUTS TARGET PRICE TO $91 FROM $94
Reuters · 7h ago
Oppenheimer Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
TipRanks · 8h ago
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
TipRanks · 8h ago
Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Universal Health (UHS)
TipRanks · 8h ago
Scotiabank Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)
TipRanks · 8h ago
BIOMARIN PHARMACEUTICAL, INC. <BMRN.O>: WELLS FARGO RAISES TARGET PRICE TO $110 FROM $100
Reuters · 8h ago
BIOMARIN PHARMACEUTICAL INC <BMRN.O>: STIFEL CUTS TARGET PRICE TO $108 FROM $109
Reuters · 8h ago
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Evolent Health (EVH) and BioMarin Pharmaceutical (BMRN)
TipRanks · 8h ago
More
Webull provides a variety of real-time BMRN stock news. You can receive the latest news about Biomarin Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRN
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.